General Proximity and Daiichi Sankyo link on oncology - Pharmaceutical Technology

General Proximity and Daiichi Sankyo link on oncology  Pharmaceutical Technology

Will Sankyo Co. Ltd. (SOK) stock see valuation expansion - Trade Volume Report & Daily Technical ...

Will Sankyo Co. Ltd. (SOK) stock see valuation expansion - Trade Volume Report & Daily Technical Stock Forecast Reports  newser.com

Armand Cognetta: General Proximity Will Collaborate with Daiichi Sankyo US - Oncodaily

Armand Cognetta: General Proximity Will Collaborate with Daiichi Sankyo US  Oncodaily

General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advanc...

General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform  PR Newswire

Daiichi Sankyo partnering with General Proximity on oncology targets - MSN

Daiichi Sankyo partnering with General Proximity on oncology targets  MSN

Sankyo's (TSE:6417) Solid Earnings May Rest On Weak Foundations - simplywall.st

Sankyo's (TSE:6417) Solid Earnings May Rest On Weak Foundations  simplywall.st

Is Sankyo Co. Ltd. (SOK) stock a buy for dividend portfolios - Trade Signal Summary & Consistent ...

Is Sankyo Co. Ltd. (SOK) stock a buy for dividend portfolios - Trade Signal Summary & Consistent Profit Alerts  newser.com

Why retail traders accumulate Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock - Weekly...

Why retail traders accumulate Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock - Weekly Profit Analysis & Weekly High Return Forecasts  newser.com

Will Sankyo Co. Ltd. (SOK) stock draw ESG focused funds - July 2025 Intraday Action & Short-Term ...

Will Sankyo Co. Ltd. (SOK) stock draw ESG focused funds - July 2025 Intraday Action & Short-Term Trading Alerts  newser.com

Is Sankyo Co. Ltd. (SOK) stock attractive for dividend growth - Quarterly Growth Report & Weekly ...

Is Sankyo Co. Ltd. (SOK) stock attractive for dividend growth - Quarterly Growth Report & Weekly Top Performers Watchlists  newser.com

Is Sankyo Co. Ltd. (SOK) stock a buy for dividend portfolios - 2025 Price Momentum & AI Based Tra...

Is Sankyo Co. Ltd. (SOK) stock a buy for dividend portfolios - 2025 Price Momentum & AI Based Trade Execution Alerts  newser.com

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock benefit from sector leadership - ...

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock benefit from sector leadership - 2025 Technical Overview & Low Volatility Stock Recommendations  newser.com

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock benefit from sector leadership - ...

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock benefit from sector leadership - July 2025 Reactions & Accurate Buy Signal Alerts  newser.com

Will Sankyo Co. Ltd. (SOK) stock announce special dividend - July 2025 Analyst Calls & AI Enhance...

Will Sankyo Co. Ltd. (SOK) stock announce special dividend - July 2025 Analyst Calls & AI Enhanced Trading Signals  newser.com

Will Sankyo Co. Ltd. (SOK) stock draw ESG focused funds - 2025 Support & Resistance & Weekly Mome...

Will Sankyo Co. Ltd. (SOK) stock draw ESG focused funds - 2025 Support & Resistance & Weekly Momentum Stock Picks  newser.com

Will Sankyo Co. Ltd. (SOK) stock draw ESG focused funds - Weekly Stock Analysis & Real-Time Buy Z...

Will Sankyo Co. Ltd. (SOK) stock draw ESG focused funds - Weekly Stock Analysis & Real-Time Buy Zone Alerts  newser.com

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock remain on Wall Street radar - 202...

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock remain on Wall Street radar - 2025 Earnings Impact & AI Enhanced Trading Signals  newser.com

Why Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock signals breakout potential - July ...

Why Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock signals breakout potential - July 2025 PostEarnings & Risk Controlled Stock Pick Alerts  newser.com

Daiichi Sankyo launches first-in-human trial of innovative cancer therapy - Indian Pharma Post

Daiichi Sankyo launches first-in-human trial of innovative cancer therapy  Indian Pharma Post

Why Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock signals breakout potential - Weekl...

Why Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock signals breakout potential - Weekly Stock Report & High Accuracy Swing Entry Alerts  newser.com

Daiichi Sankyo launches its STING operation against cancer - pharmaphorum

Daiichi Sankyo launches its STING operation against cancer  pharmaphorum

Can Sankyo Co. Ltd. (SOK) stock hit consensus price targets - Dollar Strength & High Yield Equity...

Can Sankyo Co. Ltd. (SOK) stock hit consensus price targets - Dollar Strength & High Yield Equity Trading Tips  newser.com

Why retail traders accumulate Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock - July 2...

Why retail traders accumulate Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock - July 2025 Drop Watch & High Return Trade Opportunity Guides  newser.com

Is Sankyo Co. Ltd. (SOK) stock a buy for dividend portfolios - July 2025 Weekly Recap & Stock Por...

Is Sankyo Co. Ltd. (SOK) stock a buy for dividend portfolios - July 2025 Weekly Recap & Stock Portfolio Risk Control  newser.com

Can Sankyo Co. Ltd. (SOK) stock hit consensus price targets - 2025 Institutional Moves & Free Wee...

Can Sankyo Co. Ltd. (SOK) stock hit consensus price targets - 2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides  newser.com

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock benefit from sector leadership - ...

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock benefit from sector leadership - July 2025 Snapshot & AI Forecasted Stock Moves  newser.com

General Proximity, Daiichi Sankyo Partner to Advance Novel Oncology Therapeutics Using OmniTAC - ...

General Proximity, Daiichi Sankyo Partner to Advance Novel Oncology Therapeutics Using OmniTAC  TradingView

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock remain on Wall Street radar - Wee...

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock remain on Wall Street radar - Weekly Market Summary & Reliable Intraday Trade Alerts  newser.com

DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ...

DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo  Business Wire

ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer - Clinical Tri...

ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer  Clinical Trials Arena

Why Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock signals breakout potential - July ...

Why Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock signals breakout potential - July 2025 Outlook & Weekly Return Optimization Alerts  newser.com

Why Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock signals breakout potential - Swing...

Why Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock signals breakout potential - Swing Trade & Reliable Volume Spike Alerts  newser.com

Is Sankyo Co. Ltd. (SOK) stock a buy for dividend portfolios - July 2025 Breakouts & Reliable Pri...

Is Sankyo Co. Ltd. (SOK) stock a buy for dividend portfolios - July 2025 Breakouts & Reliable Price Breakout Alerts  newser.com

Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives - Yah...

Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives  Yahoo Finance

Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. - ...

Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.  BioPharma Dive

Daiichi Sankyo (TSE:4568): Exploring Valuation as Investor Attention Grows - Yahoo Finance

Daiichi Sankyo (TSE:4568): Exploring Valuation as Investor Attention Grows  Yahoo Finance

How Breakthrough ESMO 2025 Oncology Data at Daiichi Sankyo (TSE:4568) Has Changed Its Investment ...

How Breakthrough ESMO 2025 Oncology Data at Daiichi Sankyo (TSE:4568) Has Changed Its Investment Story  Yahoo Finance

FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA - Pharmaceutical Technology

FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA  Pharmaceutical Technology

Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades - Bloomberg.com

Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades  Bloomberg.com

General Proximity, Daiichi Sankyo partner to advance novel oncology therapeutics using OmniTAC - ...

General Proximity, Daiichi Sankyo partner to advance novel oncology therapeutics using OmniTAC  MarketScreener

Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-frien...

Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-friendly culture  Microsoft

Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd - BioSpace

Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd  BioSpace

BioMed X and Daiichi Sankyo Launch Immuno-Oncology Research Team - Contract Pharma

BioMed X and Daiichi Sankyo Launch Immuno-Oncology Research Team  Contract Pharma

New Research Team for Multispecific Biologics in Collaboration with Daiichi Sankyo Starts at the ...

New Research Team for Multispecific Biologics in Collaboration with Daiichi Sankyo Starts at the BioMed X Institute in Heidelberg  Biotech Newswire

Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer ...

Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer  BioPharm International

Daiichi Sankyo Establishes Third Research Institute in San Diego - Business Wire

Daiichi Sankyo Establishes Third Research Institute in San Diego  Business Wire

Daiichi Sankyo Co Ltd (TSE:4568) Q2 2026 Earnings Report Preview: What To Expect - Yahoo Finance

Daiichi Sankyo Co Ltd (TSE:4568) Q2 2026 Earnings Report Preview: What To Expect  Yahoo Finance

Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation - Yahoo Finance

Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation  Yahoo Finance

Will Sankyo Co. Ltd. (SOK) stock see valuation expansion - July 2025 Market Mood & High Return Tr...

Will Sankyo Co. Ltd. (SOK) stock see valuation expansion - July 2025 Market Mood & High Return Trade Guides  newser.com

Daiichi Sankyo (TSE:4568): Valuation Update After Enhertu’s Health Canada Approval Expands Market...

Daiichi Sankyo (TSE:4568): Valuation Update After Enhertu’s Health Canada Approval Expands Market Potential  simplywall.st

Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for...

Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative disease  PR Newswire

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy ...

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy  Yahoo Finance

What earnings margins imply for Daiichi Sankyo Company Limited (D4S) stock - July 2025 Update & H...

What earnings margins imply for Daiichi Sankyo Company Limited (D4S) stock - July 2025 Update & High Yield Stock Recommendations  newser.com

Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting Fo...

Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year  simplywall.st

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast C...

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO  Yahoo Finance

MSD and Daiichi Sankyo commence Phase III breast cancer therapy trial - Clinical Trials Arena

MSD and Daiichi Sankyo commence Phase III breast cancer therapy trial  Clinical Trials Arena

AAX Biotech Announces Collaboration with Daiichi Sankyo to Evaluate Opti-mAb® Technology in Next-...

AAX Biotech Announces Collaboration with Daiichi Sankyo to Evaluate Opti-mAb® Technology in Next-Generation Antibody Therapeutics  Cision News

Will Sankyo’s (TSE:6417) Anime Strategies Redefine Its Competitive Edge in the Gaming Market? - Y...

Will Sankyo’s (TSE:6417) Anime Strategies Redefine Its Competitive Edge in the Gaming Market?  Yahoo Finance

Daiichi-Merck's advanced lung cancer ADC sees 48% response rate in registrational trial - Fierce ...

Daiichi-Merck's advanced lung cancer ADC sees 48% response rate in registrational trial  Fierce Biotech

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lower...

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C  Business Wire

Daiichi Sankyo (TSE:4568) Surges on Breakthrough Oncology Data and Multiple New Drug Approvals - ...

Daiichi Sankyo (TSE:4568) Surges on Breakthrough Oncology Data and Multiple New Drug Approvals  simplywall.st

Sankyo Co. Reports Strong Growth in Pachinko Sales - TipRanks

Sankyo Co. Reports Strong Growth in Pachinko Sales  TipRanks

Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan - BioPharm International

Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan  BioPharm International

Daiichi Sankyo and BioMed X Institute in Heidelberg to Explore Multispecific Biologics to target ...

Daiichi Sankyo and BioMed X Institute in Heidelberg to Explore Multispecific Biologics to target Innovative Pathways in the Tumor Microenvironment  Onco'Zine

AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics - Pharmafile

AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics  Pharmafile

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock remain on Wall Street radar - Mar...

Will Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock remain on Wall Street radar - Market Growth Report & Technical Analysis for Trade Confirmation  newser.com

ESMO 2025: Daiichi Sankyo and AstraZeneca’s Datroway results ‘unprecedented’ - The Pharma Letter

ESMO 2025: Daiichi Sankyo and AstraZeneca’s Datroway results ‘unprecedented’  The Pharma Letter

Sankyo Co. Reports Strong Growth in Pachinko Sales - The Globe and Mail

Sankyo Co. Reports Strong Growth in Pachinko Sales  The Globe and Mail

Is Daiichi Sankyo Company Limited (D4S) stock vulnerable to rate hikes - 2025 Buyback Activity & ...

Is Daiichi Sankyo Company Limited (D4S) stock vulnerable to rate hikes - 2025 Buyback Activity & Target Return Focused Picks  newser.com

Sankyo Co. Announces Significant Share Repurchase - TipRanks

Sankyo Co. Announces Significant Share Repurchase  TipRanks

Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a Ne...

Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics  Business Wire

Is Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock cheap by valuation metrics - Quarte...

Is Daiichi Sankyo Company Limited (Common Stock) (D4S0) stock cheap by valuation metrics - Quarterly Profit Report & Accurate Technical Buy Alerts  newser.com

Daiichi Sankyo Q2 2025 slides: Revenue growth overshadowed by profit decline - Investing.com

Daiichi Sankyo Q2 2025 slides: Revenue growth overshadowed by profit decline  Investing.com

Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to A...

Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C  Business Wire

Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' - Fierce P...

Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch'  Fierce Pharma

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lower...

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C  Yahoo Finance

Daiichi Sankyo Co Ltd (TSE:4568) Q2 2026 Earnings Report Preview: What To Expect - GuruFocus

Daiichi Sankyo Co Ltd (TSE:4568) Q2 2026 Earnings Report Preview: What To Expect  GuruFocus

AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enher...

AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab  Applied Clinical Trials

Daiichi Sankyo Company (TSE:4568) Is Up 5.5% After Positive ESMO 2025 Oncology Pipeline Updates -...

Daiichi Sankyo Company (TSE:4568) Is Up 5.5% After Positive ESMO 2025 Oncology Pipeline Updates - What's Changed  simplywall.st

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highl...

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC  BioSpace

Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings - B...

Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings  BioSpace

Daiichi Sankyo connects cherry blossom trees to future of oncology pipeline - Medical Marketing a...

Daiichi Sankyo connects cherry blossom trees to future of oncology pipeline  Medical Marketing and Media

Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 O...

Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 Outcomes  Applied Clinical Trials

Daiichi Sankyo (TSE:4568): Exploring Valuation After Recent Share Price Uptick - Yahoo Finance

Daiichi Sankyo (TSE:4568): Exploring Valuation After Recent Share Price Uptick  Yahoo Finance

AstraZeneca and Daiichi Sankyo's Datroway improves OS in TNBC - The Pharma Letter

AstraZeneca and Daiichi Sankyo's Datroway improves OS in TNBC  The Pharma Letter

AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study - Seeking Alpha

AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study  Seeking Alpha

Japan’s Sankyo Foods to launch GABA rice blends for mental wellness - FoodNavigator-Asia.com

Japan’s Sankyo Foods to launch GABA rice blends for mental wellness  FoodNavigator-Asia.com

Markus Kosch: Patient Safety Day at Dalichi Sankyo Europe - Oncodaily

Markus Kosch: Patient Safety Day at Dalichi Sankyo Europe  Oncodaily

Earnings call transcript: Daiichi Sankyo Q2 2025 misses EPS forecast, stock drops - Investing.com

Earnings call transcript: Daiichi Sankyo Q2 2025 misses EPS forecast, stock drops  Investing.com

FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC - Pharmaceutical Technology

FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC  Pharmaceutical Technology

AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy - ...

AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy  MedCity News

Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo - Pharmaceutical Technology

Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo  Pharmaceutical Technology

Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China - Pharmaceutical Technology

Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China  Pharmaceutical Technology

AstraZeneca, Daiichi Sankyo report Phase 3 win for Datroway in triple negative breast cancer - En...

AstraZeneca, Daiichi Sankyo report Phase 3 win for Datroway in triple negative breast cancer  Endpoints News

Daiichi Sankyo at ASCO 2025: Markus Kosch on Advancing Patient Outcomes Through Scientific Innova...

Daiichi Sankyo at ASCO 2025: Markus Kosch on Advancing Patient Outcomes Through Scientific Innovation  Oncodaily

AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data - BioSpace

AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data  BioSpace

AstraZeneca and Daiichi Sankyo Bolster Case For Enhertu In Early Breast Cancer - Citeline News & ...

AstraZeneca and Daiichi Sankyo Bolster Case For Enhertu In Early Breast Cancer  Citeline News & Insights

Michael Sapienza: Honored to Mentor for CAIA 2025, a Powerful Initiative from Daiichi Sankyo US -...

Michael Sapienza: Honored to Mentor for CAIA 2025, a Powerful Initiative from Daiichi Sankyo US  Oncodaily

AstraZeneca and Daiichi Sankyo’s New Study on Dato-DXd: What Investors Need to Know - TipRanks

AstraZeneca and Daiichi Sankyo’s New Study on Dato-DXd: What Investors Need to Know  TipRanks

Daiichi Sankyo’s Promising Phase 1 Study on HER3-DXd in NSCLC - TipRanks

Daiichi Sankyo’s Promising Phase 1 Study on HER3-DXd in NSCLC  TipRanks